ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2931

Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?

Chi Chiu Mok1, Sau Mei Tse1, Ling Yin Ho2 and Kar Li Chan1, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Lupus and pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate whether pregnancy is a risk factor for the onset of SLE in women of the reproductive age.

Methods:

Female patients who had first onset of SLE during pregnancy between the age of 15 and 49 years were identified from our SLE cohort database (year 1999-2013).  The incidence of SLE during pregnancy in women of the reproductive age was calculated by the ratio of pregnancy-onset SLE and the total number of obstetric deliveries in our hospital within the same study period (data retrieved from the obstetric registry).  The observed incidence of SLE onset during pregnancy was compared with the expected incidence of SLE in women of the reproductive age (age 15-49 years) in the general population (data retrieved from a clinical registry of all public hospitals in Hong Kong using the diagnostic codes of SLE and its related complications, and the population census data in the years 2001, 2006 and 2011) by the Chi-square test (95% asymptotic confidence intervals calculated).  The clinical presentations, course and prognosis of pregnancy-onset SLE were compared with other non-pregnancy-onset female SLE patients.

Results:

742 female SLE patients were in our cohort; 15 patients had first onset of SLE during their pregnancies (age of onset 29.5±5.3 years; 13% in first trimester, 47% in second trimester, 40% in third trimester).  Compared to non-pregnancy-onset female SLE patients (N=727), there were more renal disease, thrombocytopenia and central nervous system involvement as initial manifestations of pregnancy-onset SLE.  Three (20%) patients also qualified the diagnosis of the obstetric antiphospholipid syndrome.  Fetal outcome was poor in patients with onset of SLE during pregnancy: intrauterine death (13%), spontaneous or therapeutic abortion (33%) and preterm delivery (13%).  The maternal prognosis of pregnancy-onset SLE, however, was generally good, with good response to treatment and very infrequent disease flares on follow-up.  The SDI damage score was significantly lower in pregnancy-onset than non-pregnancy-onset SLE patients (0.33±0.49 vs 1.09±1.6; p<0.001).  There was no mortality in pregnancy-onset SLE patients (compared to 11.4% in the remaining cohort).  The total number of deliveries registered in our hospital in women of the age 15-49 years between 1999 and 2013 was 71224.  The observed incidence of SLE during pregnancy was 0.014/1000 person-year.  During the same time period, the incidence of new onset SLE in all public hospitals in Hong Kong relative to the mean female population (15-49 years of age) from 1999 to 2013 was 0.077/1000 person-year.  The odds ratio (OR) of having new onset SLE during pregnancy was 0.22 (95%CI 0.13-0.39; p<0.001). 

Conclusion:

In women of the reproductive age, pregnancy protects against the development of SLE.  First onset of SLE during pregnancy often leads to poor fetal outcome.  However, the maternal outcome of pregnancy-onset SLE is generally good, with good response to treatment, infrequent relapse of organ manifestations and smaller risk of organ damage in the long run.


Disclosure: C. C. Mok, None; S. M. Tse, None; L. Y. Ho, None; K. L. Chan, None.

To cite this abstract in AMA style:

Mok CC, Tse SM, Ho LY, Chan KL. Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/is-pregnancy-a-risk-factor-for-the-onset-of-systemic-lupus-erythematosus-sle-in-women-of-the-reproductive-age-a-population-based-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-pregnancy-a-risk-factor-for-the-onset-of-systemic-lupus-erythematosus-sle-in-women-of-the-reproductive-age-a-population-based-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology